CLENE INC (CLNN)
US1856342019 - Common Stock
CLNN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. CLNN has a bad profitability rating. Also its financial health evaluation is rather negative. CLNN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CLNN had negative earnings in the past year.
In the past year CLNN has reported a negative cash flow from operations.
In the past 5 years CLNN always reported negative net income.
In the past 5 years CLNN always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -114.11%, CLNN is not doing good in the industry: 78.94% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -114.11% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-59.09%
ROA(5y)-41.29%
ROE(3y)-456.82%
ROE(5y)-1408.41%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 78.62%, CLNN belongs to the top of the industry, outperforming 86.37% of the companies in the same industry.
CLNN's Gross Margin has improved in the last couple of years.
CLNN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 78.62% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.93%
GM growth 5YN/A
2. Health
2.1 Basic Checks
CLNN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CLNN has less shares outstanding
Compared to 5 years ago, CLNN has more shares outstanding
CLNN has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -15.00, we must say that CLNN is in the distress zone and has some risk of bankruptcy.
CLNN has a Altman-Z score of -15.00. This is amonst the worse of the industry: CLNN underperforms 82.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -15 |
ROIC/WACCN/A
WACC12.16%
2.3 Liquidity
A Current Ratio of 0.83 indicates that CLNN may have some problems paying its short term obligations.
CLNN has a Current ratio of 0.83. This is amonst the worse of the industry: CLNN underperforms 90.62% of its industry peers.
CLNN has a Quick Ratio of 0.83. This is a bad value and indicates that CLNN is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of CLNN (0.82) is worse than 90.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.83 | ||
| Quick Ratio | 0.82 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 43.83% over the past year.
CLNN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -41.53%.
CLNN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 46.03% yearly.
EPS 1Y (TTM)43.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-205%
Revenue 1Y (TTM)-41.53%
Revenue growth 3Y46.03%
Revenue growth 5YN/A
Sales Q2Q%-19.44%
3.2 Future
CLNN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.87% yearly.
The Revenue is expected to grow by 230.09% on average over the next years. This is a very strong growth
EPS Next Y55.04%
EPS Next 2Y29.02%
EPS Next 3Y21.51%
EPS Next 5Y20.87%
Revenue Next Year-34.68%
Revenue Next 2Y-28.68%
Revenue Next 3Y337.57%
Revenue Next 5Y230.09%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CLNN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLNN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CLNN's earnings are expected to grow with 21.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.02%
EPS Next 3Y21.51%
5. Dividend
5.1 Amount
CLNN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CLENE INC
NASDAQ:CLNN (1/14/2025, 8:00:01 PM)
4.8
-0.15 (-3.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners12.86%
Inst Owner Change-0.16%
Ins Owners13.44%
Ins Owner Change0.67%
Market Cap38.30M
Analysts81.67
Price Target46.07 (859.79%)
Short Float %1.8%
Short Ratio1.15
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.96%
Min EPS beat(2)9.66%
Max EPS beat(2)30.25%
EPS beat(4)3
Avg EPS beat(4)12.12%
Min EPS beat(4)-10.29%
Max EPS beat(4)30.25%
EPS beat(8)5
Avg EPS beat(8)10.75%
EPS beat(12)8
Avg EPS beat(12)25.79%
EPS beat(16)10
Avg EPS beat(16)8.37%
Revenue beat(2)0
Avg Revenue beat(2)-8.01%
Min Revenue beat(2)-10.78%
Max Revenue beat(2)-5.23%
Revenue beat(4)1
Avg Revenue beat(4)-10.72%
Min Revenue beat(4)-41.81%
Max Revenue beat(4)14.94%
Revenue beat(8)3
Avg Revenue beat(8)17.19%
Revenue beat(12)5
Avg Revenue beat(12)21.56%
Revenue beat(16)8
Avg Revenue beat(16)37.09%
PT rev (1m)0%
PT rev (3m)-5.9%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1201.14%
EPS NY rev (1m)1.04%
EPS NY rev (3m)12.41%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.23%
Revenue NY rev (3m)-3.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 90.98 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-5.28
EYN/A
EPS(NY)-3.49
Fwd EYN/A
FCF(TTM)-2.97
FCFYN/A
OCF(TTM)-2.96
OCFYN/A
SpS0.05
BVpS-0.52
TBVpS-0.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -114.11% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 78.62% | ||
| FCFM | N/A |
ROA(3y)-59.09%
ROA(5y)-41.29%
ROE(3y)-456.82%
ROE(5y)-1408.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.93%
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 3.24% | ||
| Cap/Sales | 12.83% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.83 | ||
| Quick Ratio | 0.82 | ||
| Altman-Z | -15 |
F-Score3
WACC12.16%
ROIC/WACCN/A
Cap/Depr(3y)221.91%
Cap/Depr(5y)N/A
Cap/Sales(3y)445.77%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-205%
EPS Next Y55.04%
EPS Next 2Y29.02%
EPS Next 3Y21.51%
EPS Next 5Y20.87%
Revenue 1Y (TTM)-41.53%
Revenue growth 3Y46.03%
Revenue growth 5YN/A
Sales Q2Q%-19.44%
Revenue Next Year-34.68%
Revenue Next 2Y-28.68%
Revenue Next 3Y337.57%
Revenue Next 5Y230.09%
EBIT growth 1Y18.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.47%
EBIT Next 3Y12.42%
EBIT Next 5Y39.19%
FCF growth 1Y47.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.22%
OCF growth 3YN/A
OCF growth 5YN/A